Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744296 · ClinicalTrials.gov registry record
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
A clinical trial of Squamous Cell Carcinoma of Head and Neck, sponsored by Massachusetts Eye and Ear Infirmary.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT06744296 is a study of Squamous Cell Carcinoma of Head and Neck that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 75 participants, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06744296, a study of Squamous Cell Carcinoma of Head and Neck, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
Conditions Studied
Interventions
- OTHER Blood Draws and Tissue Sample(s)
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2029-01-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06744296
The ClinicalTrials.gov registry entry for NCT06744296 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168-participant average among 37 other Squamous Cell Carcinoma of Head and Neck trials with a reported enrollment target (55% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Carcinoma of Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which Blood Draws and Tissue Sample(s) is the first listed.
NCT06744296 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06744296 about?
NCT06744296 is a clinical study titled "Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck". This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.
What is the current status of trial NCT06744296?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2025-02-03. Estimated completion is 2029-01-06.
What conditions does trial NCT06744296 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma of Head and Neck.
What interventions are being tested in trial NCT06744296?
The interventions under investigation include: Blood Draws and Tissue Sample(s) (OTHER).
Who is sponsoring clinical trial NCT06744296?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06744296 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma of Head and Neck
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
RECRUITING · Phase 2
-
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RECRUITING · Phase 3
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.